Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2980890 | 1.00 | PRKCA (0.39) | PRKCAELANE | |
| SCHEMBL3517295 | 0.81 | PRKCA (0.39) | PRKCAELANE | |
| SCHEMBL2984809 | 0.79 | — | — | |
| SCHEMBL2982487 | 0.79 | — | — | |
| SCHEMBL16077777 | 0.76 | PRKCA (0.36) | PRKCAELANE | |
| SCHEMBL16077780 | 0.76 | TSHR (0.41) | PRKCA | |
| SCHEMBL8211801 | 0.74 | PRKCA (0.45) | PRKCAELANE | |
| SCHEMBL2478389 | 0.74 | TSHR (0.48) | PRKCAELANE | |
| SCHEMBL2982725 | 0.73 | ELANE (0.32) | ELANE | |
| SCHEMBL2984786 | 0.73 | ELANE (0.32) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125702-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | Xenoport, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | claimed |
| WO-2008076458-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| US-8324272-B2 | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324273-B2 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709527-B2 | 2-acetyloxy-1-methylpropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Parkinson's disease; crystalline forms; improved pharmacokinetics; oral administration | XENOPORT, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | XENOPORT, INC. | 2008-07-17 | — | — | US | disclosed |
| WO-2008079387-A1 | CATECHOL PROTECTED LEVODOPA DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, DDT, DDC | PRKCA 3356/4885ELANE 1408/4885 |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | COMT, DDT, DDC | PRKCA 3406/4885ELANE 1246/4885 |
| US-20080171789-A1 | Catechol protected levodopa diester prodrugs, compositions, and methods of use | COMT, PARK7, DDT | PRKCA 3142/4885ELANE 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.